Hikma Prepares For Push Into MENA Oncology Biologics Market

 
• By Aidan Fry

Having enjoyed some success in the Middle East and North Africa region with its Remsima infliximab biosimilar for autoimmune disorders, Hikma is lining up launches of both rituximab and trastuzumab into the region’s oncology arena.

Middle_East_Map
Hikma is preparing to introduce rituximab and trustuzmab biosimilars in the Middle East and North Africa region • Source: Shutterstock

More from Biosimilars

More from Products